Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment

Br J Clin Pharmacol. 2019 May;85(5):1039-1040. doi: 10.1111/bcp.13878. Epub 2019 Mar 4.

Authors

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Imperial College London, London, UK.
² Department of HIV & Genitourinary Medicine, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK.
³ Department of Pharmacology, University of Liverpool, Liverpool, UK.
⁴ Department of HIV & Genitourinary Medicine, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
⁵ Clinical Development, Allergan plc, South San Francisco, California.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-HIV Agents / cerebrospinal fluid
Anti-HIV Agents / pharmacokinetics*
Anti-HIV Agents / therapeutic use
CCR5 Receptor Antagonists / administration & dosage*
Cognition / drug effects
Cognitive Dysfunction / cerebrospinal fluid
Cognitive Dysfunction / drug therapy*
Cognitive Dysfunction / etiology
HIV Infections / cerebrospinal fluid
HIV Infections / complications*
HIV Infections / drug therapy
HIV Infections / virology
HIV-1 / genetics
HIV-1 / isolation & purification
Humans
Imidazoles / cerebrospinal fluid
Imidazoles / pharmacokinetics*
Imidazoles / therapeutic use
RNA, Viral / cerebrospinal fluid
Sulfoxides

Substances

Anti-HIV Agents
CCR5 Receptor Antagonists
Imidazoles
RNA, Viral
Sulfoxides
cenicriviroc